Duchenne Muscular Dystrophy: Clinical Innovations, Ethical Considerations, and Evolving the Path to Adulthood

Area of Science:

• Neurology
• Genetics
• Bioethics

Background:

• Duchenne Muscular Dystrophy (DMD) is a severe, progressive neuromuscular disorder.
• Recent advancements in genetic and molecular therapies are transforming DMD treatment paradigms.
• The extended lifespan and improved outcomes in DMD necessitate addressing complex ethical and psychosocial challenges.

Purpose of the Study:

• To comprehensively review the evolving landscape of DMD management.
• To explore the long-term and ethical considerations of emerging experimental therapies for DMD.
• To examine the psychosocial impacts of DMD and its treatments on patients and caregivers, particularly during the transition to adulthood.

Main Methods:

• Literature review synthesizing current research on DMD therapies.
• Analysis of ethical discourse surrounding novel treatment modalities.
• Exploration of psychosocial factors impacting individuals with DMD and their families.

Main Results:

• Novel therapies like exon skipping, gene therapy, and CRISPR-based approaches are advancing DMD treatment.
• These breakthroughs present significant ethical dilemmas and psychosocial challenges.
• There is a growing need for autonomy-supportive environments and multidisciplinary care models for individuals with DMD transitioning to adulthood.

Conclusions:

• The evolving treatment landscape for DMD requires a holistic approach, integrating biological, ethical, and psychosocial considerations.
• Multidisciplinary care is critical to support individuals with DMD throughout their lives, especially during the transition to adulthood.
• Addressing the complex needs of an aging DMD population requires continuous adaptation of care models and ethical frameworks.